PMID- 17646097
OWN - NLM
STAT- MEDLINE
DCOM- 20071227
LR  - 20220409
IS  - 0960-0760 (Print)
IS  - 0960-0760 (Linking)
VI  - 107
IP  - 1-2
DP  - 2007 Oct
TI  - Transcriptional analysis of steroid hormone receptors in smooth muscle uterine 
      leiomyoma tumors of postmenopausal patients.
PG  - 42-7
AB  - Smooth muscle tumors are histologically separated into benign leiomyomas and 
      malignant leiomyosarcomas. Uterine leiomyomas represent benign clonal tumors 
      often arising within the smooth muscle tissue of the human uterus. Uterine 
      leiomyomas develop after the start of the menstrual cycle, become symptomatic 
      during middle age, and in most postmenopausal patients tumor regression occurs. 
      Rarely, leiomyomas progress to leiomyosarcomas, where many sarcomas have markedly 
      reduced or no steroid hormone receptors, thus, evolve to a hormone non-responsive 
      state. Premenopausal leiomyomas are known to express higher levels of estrogen 
      receptor-alpha (ERalpha), estrogen receptor-beta (ERbeta) and progesterone 
      receptor (PGR) than control myometrium, whereas postmenopausal leiomyomas have 
      not been so well characterized molecularly. In this present investigation, 
      ERbeta, ERalpha and PGR gene expression were assessed in leiomyomas and in 
      matched adjacent myometrium from a cohort of 14 postmenopausal patients using 
      semi-quantitative Realtime PCR and RT-PCR. The mean average results showed that 
      ERbeta was 2.5-fold statistically significantly over expressed in postmenopausal 
      leiomyomas compared to patient matched myometrium (p=0.038), whereas ERalpha and 
      PGR were not significantly differently expressed. These results showed that 
      up-regulation of ERbeta occurred at the transcriptional level in postmenopausal 
      leiomyomas. Quantitation of steroid hormone receptors from benign uterine tumors 
      may be important for a more tailored therapy. In addition, a role for steroid 
      hormones, specifically ERbeta, is discussed in terms of benign tumor regression 
      or tumor maintenance in postmenopausal leiomyomas.
FAU - Strissel, Pamela L
AU  - Strissel PL
AD  - University-Clinic Erlangen, Department of Gynaecology and Obstetrics, Laboratory 
      for Molecular Medicine at the University of Erlangen-Nuremberg, University Street 
      21-23, D-91054 Erlangen, Germany. pamela.strissel@gyn.imed.uni-erlangen.de
FAU - Swiatek, Justine
AU  - Swiatek J
FAU - Oppelt, Peter
AU  - Oppelt P
FAU - Renner, Stefan P
AU  - Renner SP
FAU - Beckmann, Matthias W
AU  - Beckmann MW
FAU - Strick, Reiner
AU  - Strick R
LA  - eng
PT  - Journal Article
DEP - 20070620
PL  - England
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Progesterone)
SB  - IM
MH  - Aged
MH  - Estrogen Receptor alpha/*biosynthesis
MH  - Estrogen Receptor beta/*biosynthesis
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Leiomyoma/*metabolism
MH  - Middle Aged
MH  - Myometrium/metabolism
MH  - Postmenopause/*metabolism
MH  - RNA, Messenger/biosynthesis
MH  - Receptors, Progesterone/*biosynthesis
MH  - Uterine Neoplasms/*metabolism
EDAT- 2007/07/25 09:00
MHDA- 2007/12/28 09:00
CRDT- 2007/07/25 09:00
PHST- 2006/12/20 00:00 [received]
PHST- 2007/02/20 00:00 [accepted]
PHST- 2007/07/25 09:00 [pubmed]
PHST- 2007/12/28 09:00 [medline]
PHST- 2007/07/25 09:00 [entrez]
AID - S0960-0760(07)00146-X [pii]
AID - 10.1016/j.jsbmb.2007.02.005 [doi]
PST - ppublish
SO  - J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):42-7. doi: 
      10.1016/j.jsbmb.2007.02.005. Epub 2007 Jun 20.